PaclitaxelRecent, repeatedEvidence- NCT07621601 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · live · comparator · “Irinotecan; Paclitaxel; Docetaxel” · registered May 2026
- NCT07554456 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Apr 2026
- NCT07487896 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Mar 2026
- NCT07481058 · Beijing Konruns Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Paclitaxel” · registered Mar 2026
- NCT07263919 · Akeso · Phase 2 · live · background · “Paclitaxel” · registered Nov 2025
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 1213 studies | 1111 studies | comparator 9 · background 11 |
CisplatinRecent, repeatedEvidence- NCT07700667 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 2 · live · background · “Cisplatin” · registered Jul 2026
- NCT07554456 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Cisplatin” · registered Apr 2026
- NCT07481058 · Beijing Konruns Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Cisplatin” · registered Mar 2026
- NCT07263919 · Akeso · Phase 2 · live · background · “Cisplatin” · registered Nov 2025
- NCT06852456 · Qilu Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Cisplatin” · registered Feb 2025
| Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed | 1010 studies | 910 studies | background 16 · comparator 3 |
FluorouracilRecent, repeatedEvidence- NCT07730021 · Astellas Pharma Inc · Phase 2 · live · background · “5-fluorouracil” · registered Jul 2026
- NCT07733180 · BeOne Medicines · Phase 2 · live · background · “5-fluorouracil (5-FU)” · registered Jul 2026
- NCT07700667 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 2 · live · background · “5 - FU” · registered Jul 2026
- NCT07554521 · BeOne Medicines · Phase 2 · live · background · “5-fluorouracil (5-FU)” · registered Apr 2026
- NCT06780111 · Merck & Co., Inc · Phase 2 · live · background · “5-Fluorouracil (5-FU)” · registered Jan 2025
| Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed | 78 studies | 79 studies | background 16 |
IrinotecanRecent, repeatedEvidence- NCT07621601 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · live · comparator · “Irinotecan; Paclitaxel; Docetaxel” · registered May 2026
- NCT07487896 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Irinotecan” · registered Mar 2026
- NCT06644781 · Daiichi Sankyo · Phase 3 · live · comparator · “Irinotecan hydrochloride (HCl)” · registered Oct 2024
- NCT06194734 · Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Irinotecan” · registered Dec 2023
- NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Irinotecan” · registered Jul 2023
| Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016) | 67 studies | 77 studies | comparator 7 · background 3 |
OxaliplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07730021 · Astellas Pharma Inc · Phase 2 · live · background · “Oxaliplatin” · registered Jul 2026
- NCT07733180 · BeOne Medicines · Phase 2 · live · background · “Oxaliplatin” · registered Jul 2026
- NCT07554521 · BeOne Medicines · Phase 2 · live · background · “Oxaliplatin” · registered Apr 2026
- NCT06780111 · Merck & Co., Inc · Phase 2 · live · background · “Oxaliplatin” · registered Jan 2025
- NCT06247956 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · comparator · “Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection” · registered Jan 2024
| Sanofi35% of its industry studies | 56 studies | 56 studies | background 9 · comparator 1 |
pembrolizumabRecent, repeatedEvidence- NCT07730021 · Astellas Pharma Inc · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
- NCT06747585 · Alentis Therapeutics AG · Phase 2 · live · background · “Pembrolizumab” · registered Dec 2024
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Aug 2023
- NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2023
- NCT05144698 · Rapa Therapeutics LLC · Phase 2 · live · background · “Pembrolizumab (PD-1 Blocking Antibody)” · registered Nov 2021
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 44 studies | 55 studies | background 5 |
DocetaxelRecent, repeatedEvidence- NCT07621601 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · live · comparator · “Irinotecan; Paclitaxel; Docetaxel” · registered May 2026
- NCT07487896 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Docetaxel” · registered Mar 2026
- NCT06644781 · Daiichi Sankyo · Phase 3 · live · comparator · “Docetaxel” · registered Oct 2024
- NCT06194734 · Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Docetaxel” · registered Dec 2023
- NCT03430843 · BeOne Medicines · Phase 3 · comparator · “Docetaxel” · registered Jan 2018
| Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized | 44 studies | 44 studies | comparator 5 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07730021 · Astellas Pharma Inc · Phase 2 · live · background · “Carboplatin” · registered Jul 2026
- NCT06535607 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Jul 2024
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Carboplatin” · registered Aug 2023
| Eli Lilly and Company16% of its industry studies | 33 studies | 33 studies | background 3 |
LeucovorinRecent, repeatedEvidence- NCT07733180 · BeOne Medicines · Phase 2 · live · background · “Leucovorin” · registered Jul 2026
- NCT07554521 · BeOne Medicines · Phase 2 · live · background · “Leucovorin” · registered Apr 2026
- NCT06780111 · Merck & Co., Inc · Phase 2 · live · background · “Leucovorin” · registered Jan 2025
- NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Leucovorin” · registered Jul 2023
- NCT04949256 · Merck & Co., Inc · Phase 3 · background · “Leucovorin” · registered Jun 2021
| Sanofi15% of its industry studiesUS: off-patent, 24 generics marketed | 34 studies | 34 studies | background 6 |
CapecitabineRecent, repeatedEvidence- NCT07554521 · BeOne Medicines · Phase 2 · live · background · “Capecitabine” · registered Apr 2026
- NCT06247956 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · comparator · “Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection” · registered Jan 2024
- NCT04550260 · AstraZeneca · Phase 3 · live · background · “cisplatin + capecitabine” · registered Sep 2020
- NCT03783442 · BeOne Medicines · Phase 3 · background · “Capecitabine” · registered Dec 2018
- NCT03469557 · BeOne Medicines · Phase 2 · background · “Capecitabine” · registered Feb 2018
| Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized | 22 studies | 33 studies | background 4 · comparator 1 |
NivolumabRecent, repeatedEvidence- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Nivolumab” · registered Aug 2023
- NCT06022861 · Luye Pharma Group Ltd. · Phase 3 · live · comparator · “Opdivo®” · registered Aug 2023
- NCT04785820 · Hoffmann-La Roche · Phase 2 · comparator · “Nivolumab” · registered Mar 2021
| Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015) | 22 studies | 22 studies | comparator 2 · background 1 |
LevoleucovorinRecent, repeatedEvidence- NCT06780111 · Merck & Co., Inc · Phase 2 · live · background · “Levoleucovorin” · registered Jan 2025
- NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Levoleucovorin” · registered Jul 2023
- NCT04949256 · Merck & Co., Inc · Phase 3 · background · “Levoleucovorin” · registered Jun 2021
- NCT04210115 · Merck & Co., Inc · Phase 3 · background · “levoleucovorin” · registered Dec 2019
| Aurobindo Pharma100% of its industry studies | 22 studies | 22 studies | background 4 |
tislelizumabRecent, repeatedEvidence- NCT07700667 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 2 · live · background · “Tislelizumab” · registered Jul 2026
- NCT07554456 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Tislelizumab” · registered Apr 2026
| BeOne Medicines72% of its industry studiesUS: BeOne Medicines (FDA 2024)EU: BeOne Medicines (EMA 2023) | 22 studies | 22 studies | background 2 |